Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome
Designation recognizes the potential of ETX101 to address a serious condition with high unmet need.
News
listing-news
Latest News
Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform
Financing includes $63.5M Series B equity and $20M strategic non-dilutive credit facility. Capital supports accelerated scaling amid strong commercial traction with leading biopharmaceutical developers of next-generation precision medicines.
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors. Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer. Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors.
Illumina Ventures Welcomes DeepSeq.AI as the Newest Illumina Ventures Labs Company
DeepSeq.AI announced the completion of an investment from Illumina Ventures. As part of the investment transaction, Martin Moorhead, PhD, Chief AI Scientist at Illumina Ventures, will join the DeepSeq board.
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
0 selected
Generating previews...